The Drug-Drug Interactions Ontology

Last uploaded: February 11, 2016
Preferred Name

tesamorelin

ID

http://purl.obolibrary.org/obo/dinto_DB08869

ATCCode

H01AC06

binds

http://purl.obolibrary.org/obo/dinto_3911

CASRN

901758-09-6

DBBrand

egrifta

DBSynonym

tesamorelin acetate

egrifta

th9507

th-9507 acetate

n-(trans-3-hexenoyl)-human growth hormone releasing factor (1-44) acetate

th-9507

nda 22-505

Definition

Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.

has pharmacological target

http://purl.obolibrary.org/obo/dinto_3911

label

tesamorelin

prefixIRI

obo2:dinto_DB08869

prefLabel

tesamorelin

xref

National Drug Code Directory:44087-2010-3

UniProtKB:P01286

ChEBI:63626

RxList:http://www.rxlist.com/egrifta-drug.htm

PDRhealth:http://www.pdr.net/drug-summary/egrifta?druglabeli

Drugs.com:http://www.drugs.com/egrifta.html

Wikipedia:http://en.wikipedia.org/wiki/Tesamorelin

subClassOf

http://purl.obolibrary.org/obo/dinto_000055

Delete Subject Author Type Created
No notes to display